Compare MINISO Group Holding Ltd (MNSO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? MINISO Group Holding Ltd trades at $9.66 (market cap $2.65B), while State Street SPDR S&P Biotech ETF trades at $154.07 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 3.8× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 7.34% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold MINISO Group Holding Ltd for 24 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| MNSO | XBI | |
|---|---|---|
Market Cap | $2.65B | $10.11B |
Volume | 747,763 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $22.75 | $169.55 |
52-Week Low | $8.60 | $104.99 |
Typical Hold Time | 24 Days | 37 Days |
Enterprise Value | $3.52B | — |
Dividend Yield | 7.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $8.94, up 0.34% on the day, with a bearish technical signal from moving averages and a mixed earnings history. The company reported 2025 revenue of $21.44 billion and net income of $1.21 billion, with a P/E of 14.76 and P/S of 0.79 indicating reasonable valuation. Recent news highlights CFO share purchases and earnings volatility, with analyst consensus leaning bullish at 60% buy ratings.
The outlook for MNSO balances growth potential from domestic expansion against earnings inconsistency and competitive pressures. Investment appeal lies in its value metrics and operational scale, but risks include margin compression and market sentiment shifts. The stock's near-term direction hinges on sustained profitability improvements and macroeconomic conditions.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
